- Home
- DX vs AUPH Comparison
DX vs AUPH Comparison
Compare DX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- AUPH
- Stock Information
- Founded
- DX 1987
- AUPH 1993
- Country
- DX United States
- AUPH Canada
- Employees
- DX N/A
- AUPH N/A
- Industry
- DX Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DX Real Estate
- AUPH Health Care
- Exchange
- DX Nasdaq
- AUPH Nasdaq
- Market Cap
- DX 1.1B
- AUPH 1.1B
- IPO Year
- DX N/A
- AUPH 1999
- Fundamental
- Price
- DX $14.06
- AUPH $7.93
- Analyst Decision
- DX Buy
- AUPH Strong Buy
- Analyst Count
- DX 6
- AUPH 3
- Target Price
- DX $13.33
- AUPH $10.33
- AVG Volume (30 Days)
- DX 2.8M
- AUPH 1.0M
- Earning Date
- DX 01-27-2025
- AUPH 02-27-2025
- Dividend Yield
- DX 12.87%
- AUPH N/A
- EPS Growth
- DX N/A
- AUPH N/A
- EPS
- DX 1.49
- AUPH N/A
- Revenue
- DX $150,396,000.00
- AUPH $220,361,000.00
- Revenue This Year
- DX N/A
- AUPH $36.97
- Revenue Next Year
- DX $8.64
- AUPH $16.43
- P/E Ratio
- DX $9.44
- AUPH N/A
- Revenue Growth
- DX 462.25
- AUPH 38.72
- 52 Week Low
- DX $11.36
- AUPH $4.71
- 52 Week High
- DX $14.21
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- DX 77.46
- AUPH 47.47
- Support Level
- DX $13.67
- AUPH $7.50
- Resistance Level
- DX $13.85
- AUPH $8.12
- Average True Range (ATR)
- DX 0.18
- AUPH 0.27
- MACD
- DX 0.06
- AUPH 0.02
- Stochastic Oscillator
- DX 87.30
- AUPH 53.49
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including residential MBS and commercial MBS.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.